Xolair
E46709
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biologic drug
ⓘ
medication ⓘ monoclonal antibody ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| commonAdverseEffect |
arthralgia
ⓘ
headache ⓘ injection site reaction ⓘ upper respiratory tract infection ⓘ |
| developedBy |
Genentech
ⓘ
Novartis ⓘ |
| hasATCCode | R03DX05 ⓘ |
| hasBlackBoxWarning | risk of anaphylaxis ⓘ |
| hasDosageForm |
prefilled syringe
ⓘ
solution for injection ⓘ vial for reconstitution ⓘ |
| hasDrugClass |
anti-IgE antibody
ⓘ
immunomodulator ⓘ |
| hasGenericName | omalizumab ⓘ |
| hasMolecularTarget | circulating IgE ⓘ |
| hasRouteOfAdministration |
subcutaneous
ⓘ
subcutaneous injection ⓘ |
| indicatedFor |
patients with chronic spontaneous urticaria refractory to H1-antihistamine treatment
ⓘ
patients with inadequately controlled moderate to severe persistent asthma ⓘ patients with positive skin test or in vitro reactivity to a perennial aeroallergen ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| marketedBy |
Genentech
ⓘ
Novartis ⓘ |
| mechanismOfAction |
binds to free IgE
ⓘ
prevents IgE from binding to high-affinity IgE receptors (FcεRI) ⓘ reduces allergic inflammatory response ⓘ |
| reduces |
expression of FcεRI receptors on mast cells and basophils
ⓘ
free IgE levels ⓘ |
| regulatoryApprovalYear |
2003 (FDA, asthma)
ⓘ
2014 (FDA, chronic idiopathic urticaria) ⓘ |
| requiresMonitoring |
asthma control
ⓘ
hypersensitivity reactions ⓘ signs and symptoms of anaphylaxis ⓘ |
| seriousAdverseEffect |
anaphylaxis
ⓘ
eosinophilic conditions ⓘ hypersensitivity reaction ⓘ serum sickness ⓘ |
| targets |
IgE
ⓘ
immunoglobulin E ⓘ |
| usedFor |
allergic asthma
ⓘ
chronic idiopathic urticaria ⓘ chronic spontaneous urticaria ⓘ moderate to severe allergic asthma ⓘ nasal polyps ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.